Drugs / VGB-R04
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05152732 | Dec 2021 → Mar 2025 | hemophilia B | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05441553 | Jul 2022 → Jan 2025 | hemophilia B | Shanghai Vitalgen BioPharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGB-R04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05152732 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “VGB-R04 is a novel AAV vector carrying a high specific activity factor IX variant.” NCT05152732 ↗ |
| Route | Intravenous | “Single intravenous (i.v.) infusion of VGB-R04” NCT05152732 ↗ |